Summary: HoneyNaps has launched its FDA-cleared artificial intelligence (AI) sleep disorder diagnostic software, Somnum, in two US medical institutions. Somnum uses deep learning-based AI to analyze biometric signals in real time to assist in diagnosing sleep and respiratory-related disorders. The software is part of HoneyNaps’ expansion into the US market, focusing on sleep health research for seniors and sleep improvement programs.
Three Key Takeaways:
- HoneyNaps’ Somnum software uses AI to perform real-time analysis of biometric data for diagnosing sleep and respiratory-related disorders.
- The Somnum software has begun being used in the US, with two medical institutions now implementing the tool.
- HoneyNaps aims to capture 10% of the US sleep medicine market within three years, leveraging its B2B business and partnerships through its US subsidiary.
HoneyNaps has officially begun supplying its artificial intelligence (AI) sleep disorder diagnostic software, Somnum, to two medical institutions in the United States.
Somnum, which was cleared by the US Food and Drug Administration in 2023, leverages deep learning-based AI to perform real-time analysis of multi-channel/temporal and large-scale biometric signals to aid in the diagnosis of sleep and respiratory-related sleep disorders.
The autoscoring software was developed using explainable medical AI (XAI, eXplainable AI) technology.
The Somnum solution will be introduced into research on sleep health for seniors and the verification of sleep improvement programs. HoneyNaps has signed a licensing agreement based on annual usage fees for the software.
HoneyNaps is currently strengthening its B2B business with major companies in South Korea while simultaneously focusing on local sales through its US subsidiary in Boston and its West Coast dealer channels, expecting continuous growth in export volume.
A HoneyNaps representative says in a release, “The US is the largest sleep medicine market in the world and still holds significant growth potential. As we officially enter the US market, we will solidify our business strategy to achieve a 10% market share within three years.”
Photo caption: Somnum
Photo credit: HoneyNaps
Leave a Reply